Key Takeaways
- Pathology groups expanding into molecular testing must ensure proper CLIA certification, robust validation documentation and realistic staffing plans before go-live.
- Reimbursement landscape analysis, including Medicare coverage, LCD/NCD changes and payor policies, should drive test menu decisions.
- Compliance infrastructure, including proficiency testing, quality assurance and documentation workflows, must be built in from the start, not retrofitted after launch.
Many pathology groups have a common misunderstanding when expanding into molecular testing: underestimating the operational burden of later proving that the tests they performed were validated, controlled and reproducible. This becomes evident when the groups are questioned by a surveyor, payor or buyer when documentation and day-to-day controls are lacking.
Pathology groups across the country are evaluating whether and how to expand their molecular testing capabilities. The drivers are clear — oncology panels, pharmacogenomics and infectious disease assays increasingly are expected rather than aspirational. But the distance between deciding to offer molecular testing and actually doing it in a compliant, sustainable way is where most of the real work occurs.
Start with these five considerations.
1. CLIA specialty and subspecialty requirements are not optional, and they are not always intuitive.
Adding molecular testing may require your laboratory to obtain additional Clinical Laboratory Improvement Amendments (CLIA) subspecialty or higher complexity certification or meet new personnel qualifications. The requirements differ depending on whether you are performing high-complexity testing in-house or relying on validated platforms that offer more automated workflows. Mapping a planned test menu to the correct CLIA complexity classifications early on avoids costly surprises during survey. For CLIA-exempt states such as New York, the requirements can be even more stringent.
2. Validation is where ambition meets operational reality and may not be immediate.
Every laboratory-developed test requires analytical validation, and the scope of that validation depends on the assay, the platform and the clinical claims you intend to support. Even when adopting a commercially available kit, your lab must validate performance in your hands, in your lab, on your instruments and with your patient population. Underestimating the time and resources needed for validation is the most common reason molecular expansions stall, and it is also the most common reason an otherwise successful go-live decision becomes difficult to defend when a surveyor, payor or buyer asks for the full validation record, including exact inputs, versions, sign-offs and change history. Keep in mind that algorithm updates and technical changes all need to be validated, so continually “improving” a test requires ongoing validation.
3. Reimbursement should inform your test menu.
Molecular testing reimbursement is a moving target, with Medicare coverage decisions, LCD and NCD changes, and commercial payor policies creating a patchwork that varies by test and jurisdiction. Before committing to a new assay, it is worth understanding not just the CPT code but the coverage landscape — including prior authorization requirements, clinical guidelines and any applicable Molecular Diagnostic Services Program pricing.
4. Staffing constraints shape what you can realistically offer.
The national shortage of qualified laboratory professionals is acute in molecular diagnostics, where the skill set is specialized and the training pipeline is limited. Consider whether your expansion plan accounts for recruitment timelines, competency assessment and the ongoing continuing education obligations that come with high-complexity testing. With shortages of experts, it can be tempting to rely on lab directors who oversee a number of facilities, but CLIA and certain state agencies limit the number of labs one director may manage. Ensuring you are aware of these limits is critical.
5. Oversight does not end at go-live.
Proficiency testing, quality assurance and ongoing competency documentation are continuous obligations. Accreditation bodies such as CAP have specific molecular pathology checklist requirements that go beyond general laboratory standards. Building these compliance workflows into your operations from the start is significantly easier than retrofitting them after you are already running samples.
How This Looks in Practice
A lab can pass validation in the sense that the assay performs and the clinical team is happy. Yet it can still fail a survey or an audit later because the validation record cannot be constructed upon questioning. Rather than fraud, the culprit is often ordinary operational drift: a file saved in the wrong place, a version mismatch, a missing sign-off or a change made on the bench that went undocumented.
The Readout
When molecular testing goes wrong, it can show up as delayed launches, unplanned validation, CAP checklist deficiency findings, claims denials, payor pushback and diligence questions that slow or derail deals. The consequences reach well beyond the bench. Lab directors defend the record. Finance teams absorb rework costs. Business teams explain why the growth story slipped.
Molecular testing expansion is a strategic opportunity for pathology groups willing to match clinical ambition with operational rigor. The groups that do it well tend to plan for the compliance infrastructure at the same time they plan for the science.
The Lab Protocol is for informational and educational purposes only and does not constitute legal, regulatory or compliance advice. Readers should consult qualified counsel regarding their specific circumstances.